ValiRx logo

VAL - ValiRx Share Price

0.158p 0.0  5.0%

Last Trade - 9:35am

Sector
Healthcare
Size
Micro Cap
Market Cap £1.54m
Enterprise Value £1.38m
Revenue £n/a
Position in Universe 1779th / 1827
Bullish
Bearish
Unlock VAL Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VAL Revenue Unlock VAL Revenue

Net Income

VAL Net Income Unlock VAL Revenue

Normalised EPS

VAL Normalised EPS Unlock VAL Revenue

PE Ratio Range

VAL PE Ratio Range Unlock VAL Revenue

Dividend Yield Range

VAL Dividend Yield Range Unlock VAL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VAL EPS Forecasts Unlock VAL Revenue
Profile Summary

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.

Directors
Last Annual December 31st, 2018
Last Interim December 31st, 2018
Incorporated January 26, 2000
Public Since February 28, 2000
No. of Shareholders: n/a
No. of Employees: 12
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 1,024,057,953
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VAL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VAL
Upcoming Events for VAL
Similar to VAL
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.